Drug profile · INN
lithium citrate
LITHIUM CITRATE
lithium citrate (LITHIUM CITRATE) is a glycogen synthase kinase-3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lithium citrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lithium citrate (LITHIUM CITRATE) is a glycogen synthase kinase-3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Glycogen synthase kinase-3 inhibitor
Primary target: Glycogen synthase kinase-3
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lithium citrate?
lithium citrate (LITHIUM CITRATE) is a glycogen synthase kinase-3 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lithium citrate?
LITHIUM CITRATE is a marketed brand name for lithium citrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lithium citrate?
lithium citrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.